Paladin Advisory Group’s Edwards Lifesciences EW Stock Holding History

Paladin Advisory Group’s Portfolio EW Stock Details EW Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$59.1K	Hold	653	–	–	0.04%	148
2026 Q1	$52.3K	Hold	653	–	–	0.04%	146
2025 Q4	$55.7K	Hold	653	–	–	0.04%	146
2025 Q3	$50.8K	Sell	653 -703	-52%	-$54.9K	0.04%	145
2025 Q2	$106K	Hold	1,356	–	–	0.08%	109
2025 Q1	$98.3K	Hold	1,356	–	–	0.08%	108
2024 Q4	$100K	Hold	1,356	–	–	0.08%	114
2024 Q3	$89.5K	Hold	1,356	–	–	0.07%	122
2024 Q2	$122K	Hold	1,356	–	–	0.1%	105
2024 Q1	$128K	Hold	1,356	–	–	0.1%	105
2023 Q4	$103K	Hold	1,356	–	–	0.09%	111
2023 Q3	$93.9K	Hold	1,356	–	–	0.08%	121
2023 Q2	$128K	Hold	1,356	–	–	0.1%	111
2023 Q1	$112K	Buy	+1,356	New	+$107K	0.09%	119
2022 Q2	–	Sell	-1,356	Closed	-$140K	–	354
2022 Q1	$166K	Buy	+1,356	New	+$152K	0.14%	104

Other funds holding EW

Ninety One (UK) London, United Kingdom $44.7B AUM 17.24% 1-Year Est. Return

Wellcome Trust London, United Kingdom $9.01B AUM 12.05% 1-Year Est. Return

Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return

Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return

Parnassus Investments San Francisco, California $37.4B AUM 35.42% 1-Year Est. Return

BHIA

Birch Hill Investment Advisors Boston, Massachusetts $2.47B AUM 20.95% 1-Year Est. Return

NONA

Ninety One North America New York $2.13B AUM 9.16% 1-Year Est. Return

Robeco Institutional Asset Management Rotterdam, Netherlands $81.4B AUM 40.71% 1-Year Est. Return

SIM

Seilern Investment Management London, United Kingdom $794M AUM 6.63% 1-Year Est. Return

Paladin Advisory Group's EW Position: Q2 2026 in Review

Paladin Advisory Group held its Edwards Lifesciences (EW) position steady in Q2 2026 at 653 shares worth $59.1K. The position accounts for 0.04% of the portfolio, ranked #148.

Paladin Advisory Group first reported a position in EW in Q1 2022 and has held it in 15 quarters since. The position peaked at $166K in Q1 2022. 547 funds tracked by Wall St. Rank hold EW as of Q2 2026.

Paladin Advisory Group held 653 shares of Edwards Lifesciences worth $59.1K as of Q2 2026.
Paladin Advisory Group left its Edwards Lifesciences share count unchanged in Q2 2026.
Edwards Lifesciences made up 0.04% of Paladin Advisory Group's portfolio in Q2 2026, its #148 holding.
Paladin Advisory Group first reported a position in Edwards Lifesciences in Q1 2022 and has held it in 15 quarters since.
Paladin Advisory Group's Edwards Lifesciences position peaked at $166K in Q1 2022.
547 funds tracked by Wall St. Rank held Edwards Lifesciences as of Q2 2026.

Based on Paladin Advisory Group's 13F filing for Q2 2026, filed 28 Jul 2026.